Differential effects of vitamin D on normal human prostate epithelial and stromal cells in primary culture

Urology

Volumn 54, Issue 1, 1999, Pages 171-177

  Krill, D ^a   Stoner, J ^a   Konety, B R ^a   Becich, M J ^a,b   Getzenberg, R H ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALPHA ACTIN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; CALCITRIOL; CALCITRIOL RECEPTOR; DRUG VEHICLE; FLUTAMIDE; UVOMORULIN; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASTRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; RAT; STROMA CELL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; CELL DIVISION; CELLS, CULTURED; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE; RATS; RATS, SPRAGUE-DAWLEY; STROMAL CELLS; VITAMIN D;

EID: 0033169062     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00103-X     Document Type: Article

References (29)

1. Wingo PA, Landis S, and Ries LAG: An adjustment to the 1997 estimate for new prostate cancer cases. CA Cancer J Clin 47: 239-242, 1997.
2. Harper ME, Pike A, Peeling WB, et al: Steroids of adrenal origin metabolised by human prostatic tissue in vivo and in vitro. J Endocrinol 60: 117-125, 1974.
3. Parmar H, Phillips RH, Lightman SL, et al: Randomized controlled study of orchidectomy versus long acting D-trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet 2: 1201-1205, 1985.
4. Huggins C, and Hodges C: Studies on prostate cancer I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293-297, 1941.
5. Schwartz GG, and Hulka BS: Is vitamin D deficiency a risk factor for prostate cancer (hypothesis)? Anticancer Res 10: 1307-1311, 1990.
6. Hanchette MA, and Schwartz GG: Geographic patterns of prostate cancer mortality. Cancer 70: 2861-2869, 1992.
7. Corder EH, Guess HA, and Hulka BS: Vitamin D and prostate cancer: A prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2: 467-472, 1993.
8. 3. Cancer Res 5: 515-520, 1992.
9. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 132: 1952-1960, 1993.
10. 3 on primary cultures of human prostatic cells. Cancer Res 54: 805-810, 1994.
11. Schwartz GG, Oeler TA, Uskovic MR, et al: Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res 14: 1077-1082, 1994.
12. Habib FK: Steroid hormones and cancer: IV prostate cancer. Eur J Surg Oncol 23: 264-268, 1997.
13. Galbraith SM, and Duchesne GM: Androgens and prostate cancer: biology, pathology, and hormonal therapy. Eur J Cancer 33: 545-554, 1997.
14. Westin P, and Bergh A: Apoptosis and other mechanisms in androgen ablation treatment and androgen independent progression of prostate cancer: a review. Cancer Detect Prev 22: 476-484, 1998.
15. Krill D, Shuman M, Thompson M, et al: A simple method for the isolation and culture of epithelial and stromal cells from benign and neoplastic prostates. Urology 49: 981-988, 1997.
16. Kassen A, Sutkowski DM, Ahn H, et al: Stromal cells of the human prostate: initial isolation and characterization. Prostate 28: 89-97, 1996.
17. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J Immunol Methods 65: 55-63, 1983.
18. Hsu SM, Raine L, and Fanger H: A comparative study of the peroxidase-antiperoxidase method and avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 75: 734-738, 1981.
19. Endres DB, and Rude RK: Mineral and bone metabolism, in Burtis CA, and Ashwood ER (Eds): Tietz Textbook of Clinical Chemistry, 2nd ed. Philadelphia, WB Saunders, 1994, pp 1887-1973.
20. Thys-Jacobs S, Chan FKW, Koberle LMC, et al: Hypercalcemia due to vitamin D toxicity, in Feldman D, Glorieux FH, and Pike JW (Eds): Vitamin D. San Diego, Academic Press, 1997, pp 883-901.
21. 3 actions in LNCaP human prostate cells are androgen-dependent. Endocrinology 138: 3290-3298, 1997.
22. Culig Z, Hobish A, Cronauer MV, et al: Androgen re-ceptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Cancer Res 54: 5474-5478, 1994.
23. Labrie F: Mechanism of action and pure antiandrogenic properties of flutamide. Cancer 72: 3816-3827, 1993.
24. Konety BR, Schwarz GG, Acierno JS Jr, et al: The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ 7: 1563-1570, 1996.
25. Peehl DM, and Sellers RG: Basic FGF, EGF, and PDGF modify TGFβ-induction of smooth muscle cell phenotype in human prostatic stromal cells. Prostate 35: 125-134, 1998.
26. 3 receptor gene expression in cultured cells by serum and growth factors. J Bone Miner Res 10: 1099-1107, 1991.
27. 3 on proliferation of cancer cells in vitro. Cancer Lett 120: 65-69, 1997.
28. 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139: 1197-1207, 1998.
29. 3 analogue EB1089. Eur J Cancer 32A: 842-848, 1996.